奈西立肽与我。 - Suppr | 超能文献

Nesiritide and Me.

作者信息

Kittleson Michelle M

机构信息

Division of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.

出版信息

Circ Heart Fail. 2018 Aug;11(8):e005440. doi: 10.1161/CIRCHEARTFAILURE.118.005440.

DOI:10.1161/CIRCHEARTFAILURE.118.005440

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Nesiritide and Me.奈西立肽与我。

Circ Heart Fail. 2018 Aug;11(8):e005440. doi: 10.1161/CIRCHEARTFAILURE.118.005440.

2

Nesiritide--not verified.奈西立肽——未经证实。

N Engl J Med. 2005 Oct 6;353(14):1525-7; author reply 1525-7.

3

[Does nesiritide reduce dyspnea in decompensated heart failure?].奈西立肽是否能减轻失代偿性心力衰竭患者的呼吸困难？

Rev Assoc Med Bras (1992). 2012 Jan-Feb;58(1):11-3.

4

Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.急性失代偿性心力衰竭治疗中的争议与冲突：奈西立肽作为循证治疗方法

Pharmacotherapy. 2007 May;27(5):619-25. doi: 10.1592/phco.27.5.619.

5

The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure.ASCEND-HF试验：奈西立肽与失代偿性心力衰竭临床疗效的急性研究。

Expert Rev Cardiovasc Ther. 2012 May;10(5):557-63. doi: 10.1586/erc.12.31.

6

Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis.奈西立肽治疗急性心肌梗死合并心力衰竭患者：一项荟萃分析。

J Int Med Res. 2020 Jan;48(1):300060519897194. doi: 10.1177/0300060519897194.

7

Nesiritide is beneficial or harmful to patients with decompensated acute congestive heart failure.奈西立肽对失代偿性急性充血性心力衰竭患者有益还是有害。

Int J Cardiol. 2015;187:387-8. doi: 10.1016/j.ijcard.2015.03.287. Epub 2015 Mar 20.

8

The lost decade of nesiritide.奈西立肽的失落十年。

N Engl J Med. 2011 Jul 7;365(1):81-2. doi: 10.1056/NEJMe1103116.

9

Nesiritide, heart failure, and renal dysfunction: irrational exuberance or throwing the baby out with the bathwater. Editorial to: "Impact of nesiritide on renal function and mortality in patients suffering from heart failure" by Dontas et al.奈西立肽、心力衰竭与肾功能不全：是过度乐观还是因噎废食。对唐塔斯等人所著《奈西立肽对心力衰竭患者肾功能及死亡率的影响》的编者按

Cardiovasc Drugs Ther. 2009 Jun;23(3):183-6. doi: 10.1007/s10557-009-6169-4.

10

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).临床试验地点入组情况对患者特征、方案完成情况及终点的影响：来自ASCEND-HF试验（奈西立肽治疗失代偿性心力衰竭的临床疗效急性研究）的见解

Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.116.002986.

引用本文的文献

1

Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.基于利钠肽的新型疗法：针对疾病状态优化的漫长药物研发历程。

Biology (Basel). 2022 Jun 3;11(6):859. doi: 10.3390/biology11060859.